Ipamorelin vs MK-677: how the two GH secretagogues differ

Last updated 2026-07-24

What are ipamorelin and MK-677, exactly?

Both belong to the growth hormone secretagogue (GHS) family, compounds that push the pituitary to release more growth hormone by acting on the ghrelin receptor (GHS-R1a) or a related pathway. That's where the similarity mostly ends. Ipamorelin is a pentapeptide, first characterized in the late 1990s as "the first selective growth hormone secretagogue," meaning it releases GH without the meaningful cortisol, prolactin, or ACTH bump seen with earlier peptides like GHRP-6 ^[1]. It was developed alongside a related medicinal chemistry program that produced a whole series of potent GH-releasing peptides derived from the same scaffold ^[2], and follow-up work described additional hybrid analogs combining ipamorelin with other secretagogue chemotypes ^[3]. MK-677 (ibutamoren) came out of a parallel line of research into orally active, non-peptide GH secretagogues. A 1998 medicinal chemistry paper describes the development of "novel orally active growth hormone secretagogues," the chemical family MK-677 belongs to ^[4]. Unlike ipamorelin, MK-677 isn't a peptide at all; it's a small molecule built specifically to survive digestion and stay active when swallowed, which is the whole reason it exists as a pill rather than an injection. Both compounds ultimately raise GH and downstream IGF-1, but they get there through different structural routes and very different pharmacokinetics, which is really the whole story of how to choose between them.

Ipamorelin vs MK-677: the head-to-head comparison

Here's the direct comparison across the variables people actually care about when picking one over the other.

How do they compare on GH release mechanism?

Both work through the ghrelin receptor system, but the selectivity data is where ipamorelin has a documented edge. The 1998 European Journal of Endocrinology paper that named it "the first selective growth hormone secretagogue" reported that ipamorelin releases GH with little to no accompanying rise in cortisol, aldosterone, or prolactin, unlike earlier GHRPs ^[1]. That selectivity was the actual point of developing it: earlier secretagogues like GHRP-6 reliably raised GH but dragged along unwanted hormonal noise. Animal work backs the mechanism further. A 1999 study found ipamorelin induces longitudinal bone growth in rats ^[7], and a follow-up histopathology paper looked at the somatotroph (GH-producing cell) response in young female rats after chronic ipamorelin treatment ^[8], giving some tissue-level evidence for how repeated dosing affects the pituitary gland itself over time. MK-677's mechanism is the same receptor family, different molecule, different oral bioavailability profile. The original chemistry papers describing this compound class emphasize that the whole design goal was oral activity, something peptides like ipamorelin cannot achieve because peptides get broken down by digestive enzymes before they reach the bloodstream ^[4]. That's a genuine mechanistic difference, more than a delivery preference: MK-677 had to be a different kind of molecule to survive the gut.

Which one has better clinical or research evidence?

Neither compound has FDA-approved indications, so "better evidence" means better characterized in controlled studies, not proven safe and effective for a specific approved use. Ipamorelin has the deeper and more diverse research trail. Beyond the original selectivity study ^[1], it has been tested in a randomized, controlled proof-of-concept trial for postoperative ileus after bowel resection ^[9], in rodent models of gastric dysmotility and postoperative ileus ^[10][11], for bone mineral content changes in adult female rats ^[12], and for its ability to counteract glucocorticoid-induced loss of bone formation in adult rats ^[13]. There's also nociception (pain) research: a 2020 paper found ghrelin mimetics, including ipamorelin, attenuate visceral and somatic nociception in preclinical models ^[14]. And metabolic work has looked at nitrogen balance and urea synthesis effects when GH secretagogues are combined with steroid treatment in rats ^[15]. More recent reviews have started grouping ipamorelin into the broader orthopaedic and sports medicine peptide literature. A 2026 JAAOS Global Research & Reviews paper on therapeutic peptides in orthopaedics discusses applications and open challenges for this class ^[16], and a 2026 American Journal of Sports Medicine primer covers injectable peptide therapy for orthopaedic and sports medicine physicians generally ^[17]. A 2026 Sports Medicine review specifically assessed safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance use ^[18], which is the kind of source you want before assuming any of this is settled science for performance goals. MK-677's public research profile leans more on body composition and hypogonadism-adjacent contexts. A 2020 Translational Andrology and Urology paper looked at growth hormone secretagogues, as a class, in managing body composition in hypogonadal males, going "beyond the androgen receptor" ^[19]. That paper is about the secretagogue class broadly, not a head-to-head ipamorelin vs MK-677 trial, so don't stretch it further than it goes.

How do side effects and safety profiles compare?

The honest answer is that a formal, controlled, side-by-side ipamorelin vs MK-677 safety trial doesn't exist in the sources available here. What exists is safety data on each compound (and the class) separately, plus some pointed warnings about the unregulated market both drugs live in. Ipamorelin's selectivity advantage, low cortisol and prolactin impact ^[1], is the main safety argument in its favor relative to older GHRPs. Metabolic research also found GH secretagogues can independently stimulate adiposity (fat tissue growth) through a GH-independent mechanism in animal models ^[20], and a separate paper described ipamorelin's mechanism of evoking insulin release from the pancreas in normal and diabetic rats ^[21], both worth knowing if you're tracking blood sugar or body composition effects closely. For the class broadly, a 2026 International Journal of Molecular Sciences review covers therapeutic peptides across aesthetic, metabolic, and endocrine conditions, including safety data and clinical application boundaries ^[22], and a 2026 Frontiers in Aging paper reviews therapeutic peptides in gerontology, mechanisms and applications for healthy aging use cases ^[23], which is relevant if you're considering either compound for age-related GH decline rather than a specific medical condition. The biggest practical safety issue with both drugs isn't the molecule itself, it's the supply chain. A 2018 Growth Hormone & IGF Research analysis of black market growth-promoting products found meaningful quality and identity problems in unregulated peptide products sold outside legitimate pharmacy channels ^[24]. That's a strong argument for sourcing through a provider-reviewed pathway rather than a gray-market vendor, regardless of which secretagogue you're considering. For a full side effect breakdown specific to ipamorelin, see ipamorelin side effects.

Ipamorelin vs MK-677 for muscle gain and fat loss: what does the evidence actually support?

This is where bodybuilding forum claims run far ahead of the data. Neither compound has a controlled human trial in these sources measuring lean mass or fat loss outcomes head-to-head, and readers should treat most of what's online about "X lbs of muscle in Y weeks" as anecdote, not evidence. What the research does support is more modest and mechanistic. GH secretagogues as a class have documented effects on nitrogen balance, meaning better protein retention under catabolic (muscle-wasting) conditions like steroid treatment, shown in a 2009 rat study ^[15]. Bone-related effects are also documented: ipamorelin increased bone mineral content in adult female rats ^[12] and counteracted glucocorticoid-induced bone loss in another rat study ^[13], both are body-composition-adjacent findings but they're about bone, not muscle mass directly. The hypogonadal male body composition paper is the closest thing to a human-relevant fat-loss and body composition discussion in this evidence set, and it frames GH secretagogues as a strategy "beyond the androgen receptor" for men with low testosterone who want body composition benefits without relying solely on testosterone replacement ^[19]. That's a specific population and a specific rationale, not a general performance-enhancement claim, and it doesn't distinguish ipamorelin from MK-677 specifically. If you're weighing dosing strategy for either compound, or specifically for a tesamorelin/ipamorelin protocol, the practical numbers are covered in ipamorelin dosage and the cjc-1295 ipamorelin dosage calculator.

Why is ipamorelin injected and MK-677 taken orally?

It comes down to molecular structure. Ipamorelin is a peptide, a short chain of amino acids, and peptides get digested by stomach acid and enzymes almost as fast as food protein does. Inject it under the skin and it bypasses the gut entirely, reaching the bloodstream directly. MK-677 was built the opposite way on purpose. The medicinal chemistry papers describing this compound class are explicit that oral activity was the design target ^[4], meaning the molecule was engineered to resist digestive breakdown and absorb through the gut wall. That's a genuine chemistry achievement, not a marketing detail, and it's the single biggest practical reason someone might prefer MK-677: no needles, no reconstitution, no injection technique to learn. The tradeoff is that oral dosing generally means a flatter, longer exposure curve compared to an injected peptide's sharper pulse. Ipamorelin's PK-PD modeling describes a short-acting pattern consistent with a pulsatile GH release, closer to how the body naturally releases GH in bursts, mostly during sleep ^[5]. Some researchers consider pulsatile dosing more physiologic; others consider it irrelevant to outcomes. Nobody has a definitive controlled trial settling that argument for either compound.

Can you take ipamorelin and MK-677 together?

There's no controlled trial data here confirming a combined ipamorelin plus MK-677 protocol, so any specific combined-dosing claim you see is extrapolation, not established science. What is documented is that ipamorelin is commonly paired with a GHRH analog rather than another ghrelin-pathway compound, because the two act on different receptors and the combination has more grounding in the growth hormone axis literature broadly. That's also the actual product reality worth knowing: there is no standalone ipamorelin product on the market. Ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend, tesamorelin being a GHRH analog, through provider-reviewed compounding pathways. That combination targets two different steps of the same GH release pathway rather than stacking two ghrelin-receptor agonists on top of each other. Stacking ipamorelin with MK-677 specifically (two ghrelin-pathway agonists) isn't something these sources evaluate, and doubling up on the same receptor pathway isn't obviously better than combining across pathways. If you're building a stack, understand the mechanism you're targeting before assuming more is better.

Are ipamorelin and MK-677 legal, and are they FDA-approved?

Neither is FDA-approved for any indication. You can confirm approval status yourself in the FDA's Drugs@FDA database ^[25], and neither compound appears there as an approved drug product. Ipamorelin's legal availability in the US runs through the pharmacy compounding framework. Compounded drugs made from bulk substances are governed by 21 U.S.C. 353a ^[26], and the FDA maintains lists of bulk drug substances that can be used under section 503A compounding and under 503B outsourcing facility rules ^[27]. Whether a given peptide is compounded legally depends on its bulk substance status on those FDA lists, and that status changes over time as the agency reviews nominations, tracked in the FDA's current nominated substances list . MK-677 is not a peptide and sits in a different, murkier space: it's not FDA-approved, isn't on the standard compounding pharmacy bulks lists in the way peptides are, and most of what's sold as "MK-677" online is an unregulated research chemical, not a pharmacy-dispensed product. That distinction matters a lot for quality control. The 2018 black market products analysis found real identity and purity problems in unregulated growth-promoting compounds sold outside legitimate channels ^[24], and that risk applies more acutely to a compound like MK-677 that typically isn't moving through pharmacy channels at all.

How does anti-doping status differ between the two?

Both are prohibited in competitive sport under WADA's growth hormone and growth hormone-releasing factor categories, and both show up in the sports medicine peptide literature as detection targets, not approved therapeutics. A 2026 JBJS Reviews narrative review specifically covers injectable peptides in sports medicine with attention to antidoping implications ^[28], which is the more relevant source if you're an athlete under any testing authority. Detection science backs this up: a 2015 Drug Testing and Analysis paper describes methods for finding growth hormone releasing peptide metabolites, including ipamorelin, in human urine after nasal administration [24 or similar peptide detection work]^[29], and a 2012 Analytical Chemistry paper covers metabolism of growth hormone releasing peptides generally, relevant to how labs detect use after the fact [13 or related][see below]. MK-677, as an oral non-peptide secretagogue, is detected through different assay methods than peptide GHRPs, but it falls under the same WADA prohibited category conceptually. If you're subject to any drug testing, competitive or occupational, assume both compounds carry real detection and violation risk, and that "it's just a peptide, it clears fast" is not a defense that holds up against modern metabolite testing.

Which is better for anti-aging or longevity use?

This is a popular framing but the evidence for either compound as a longevity intervention specifically is thin and mostly extrapolated from broader GH axis research, not dedicated aging-outcome trials. The most directly relevant source here is a 2026 Frontiers in Aging review of therapeutic peptides in gerontology, covering mechanisms and applications for healthy aging broadly ^[23]. It discusses the peptide class in this context, but it is not a controlled trial proving ipamorelin or MK-677 extends healthspan or lifespan in humans. Be skeptical of any claim that frames either compound as an anti-aging drug in the sense of a proven intervention; that's a research direction, not an established outcome. What's better supported is narrower: bone density maintenance in the face of glucocorticoid use ^[13], body composition support in a specific hypogonadal male population ^[19], and general GH axis support as people age and natural GH output declines. Those are reasonable, modest goals. "Reverse aging" is not a claim either compound's evidence base currently supports.

What about MK-677's reputation for water retention and appetite increase?

MK-677's ghrelin-receptor activity is mechanistically tied to appetite stimulation, since ghrelin is the body's primary "hunger hormone," and increased appetite is one of the most consistently reported subjective effects among people using it, though the sources here don't include a controlled human trial quantifying that effect for MK-677 specifically. Water retention is commonly reported anecdotally with GH-elevating compounds generally, tied to GH and IGF-1's effects on sodium and fluid handling, but again, this isn't a number pulled from a controlled MK-677 trial in the evidence set here; it's a class-level physiological plausibility, not a measured effect size for this specific drug. Ipamorelin's selective profile ^[1] is sometimes framed as producing less of this kind of side effect bundle compared to less selective secretagogues, but that comparison hasn't been run head-to-head against MK-677 in a controlled trial either. If appetite change or fluid retention is a dealbreaker for you, that's a real practical consideration worth discussing with a prescriber, not something to decide based on forum anecdotes.

How do you decide between ipamorelin and MK-677?

If you want an injectable, selective, short-acting approach with the deeper controlled-study track record on GH selectivity ^[1] and a documented physician-reviewed compounding pathway, ipamorelin (as part of a tesamorelin/ipamorelin blend) is the better-characterized option. If needles are a hard no and you want an oral option, MK-677 is the one built for that, but you're accepting a thinner controlled human evidence base and a market with less pharmacy-channel oversight. Don't let either choice happen through an unregulated online vendor. The 2018 black market peptide analysis found real quality failures in exactly this kind of unregulated sourcing ^[24], and that risk sits on top of whatever the drug's own effect profile looks like. A provider-reviewed pathway, where a clinician assesses your history and a real pharmacy handles fulfillment and quality control, is the responsible way to access either of these compounds if you and a prescriber decide it's appropriate. Ipamorelin Co works within that model: reviewed by a provider, dispensed as a tesamorelin/ipamorelin blend, fulfilled through a licensed pharmacy partner, not sold as a standalone raw peptide. Before starting anything, read through ipamorelin dosage and ipamorelin side effects so you know what a real protocol and a real risk conversation look like, and check reconstitute cjc ipamorelin if you're already working with an injectable blend and need the handling details right.

Frequently asked questions

Is ipamorelin or MK-677 more effective for growth hormone release?

There's no controlled human trial in the literature directly comparing GH output between the two. Ipamorelin has stronger selectivity data (minimal cortisol/prolactin rise) from its original 1998 characterization study ^[1]. MK-677's advantage is oral bioavailability, not necessarily a larger GH response. Effectiveness for your goals depends more on route and duration preference than a proven potency gap.

Does ipamorelin or MK-677 have a longer half-life?

Ipamorelin is short-acting, consistent with a pulsatile GH release pattern described in human PK-PD modeling ^[13]. MK-677 is generally described as longer-acting because it's an oral small molecule designed for sustained absorption, though a controlled human PK study establishing an exact MK-677 half-life isn't among the sources reviewed here, so treat specific hour figures cautiously.

Can I buy ipamorelin as a standalone product?

No. There is no standalone ipamorelin SKU on the legitimate market. Ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend through provider-reviewed compounding pathways. Anything sold online as pure standalone ipamorelin outside a pharmacy channel should be treated with the same skepticism the 2018 black market peptide analysis raises about unregulated products ^[17].

Is MK-677 legal to buy in the US?

MK-677 is not FDA-approved for any indication, confirmable in the Drugs@FDA database ^[28]. It's not typically handled through the same pharmacy compounding bulk-substance framework that governs peptides like ipamorelin under 21 U.S.C. 353a ^[30]. Most MK-677 sold online is an unregulated research chemical, which carries real quality and legal ambiguity risk.

Do ipamorelin and MK-677 cause the same side effects?

They overlap in category (appetite change, possible fluid retention, blood sugar effects) because both raise GH/IGF-1 through the ghrelin receptor pathway, but no controlled head-to-head trial in this evidence set directly compares side effect rates. Ipamorelin's selectivity data shows minimal cortisol/prolactin impact ^[1]; MK-677's appetite-stimulating reputation follows from ghrelin receptor pharmacology generally.

Which is better for fat loss, ipamorelin or MK-677?

Neither has a controlled human trial in this evidence set measuring fat loss outcomes head-to-head. The closest relevant human data is a 2020 paper on GH secretagogues and body composition in hypogonadal males ^[6], which discusses the class broadly, not a specific ipamorelin-vs-MK-677 comparison. Treat specific fat-loss claims for either compound as unproven for general use.

Can you stack ipamorelin and MK-677 together?

No controlled trial data supports or evaluates this specific combination in the sources reviewed here. Ipamorelin is more commonly paired with a GHRH analog like tesamorelin, targeting a different point in the GH axis, and it's dispensed that way as a tesamorelin/ipamorelin blend. Combining two ghrelin-receptor agonists isn't something the research base currently addresses.

Is ipamorelin injectable only, or is there an oral version?

Ipamorelin is a peptide and is administered by subcutaneous injection. Research has looked at nasal absorption as an alternate delivery route in animal pharmacokinetic studies ^[18], but that's not the same as an oral tablet, and no oral ipamorelin product is commercially available.

Why does MK-677 come as a pill and ipamorelin as an injection?

MK-677 is a non-peptide small molecule specifically engineered for oral activity, described in the original 1998 medicinal chemistry literature on this compound class ^[9]. Ipamorelin is a peptide, which digestive enzymes break down before it can absorb through the gut, so it has to be injected to reach the bloodstream intact.

Are ipamorelin and MK-677 banned in competitive sports?

Yes, both fall under WADA's prohibited growth hormone and GH-releasing factor categories. A 2026 JBJS Reviews narrative review covers injectable peptides in sports medicine along with antidoping detection implications ^[10]. Detection methods for GH-releasing peptide metabolites in urine have been published for compounds in ipamorelin's class ^[15].

How is ipamorelin dosed compared to MK-677?

Ipamorelin, dispensed within a tesamorelin/ipamorelin blend, is dosed by subcutaneous injection on a schedule set by a prescriber. MK-677 is dosed orally, typically once daily given its longer absorption profile. Specific dosing details for the tesamorelin/ipamorelin blend are covered in ipamorelin dosage and the dosage calculator.

Has ipamorelin been tested in humans in controlled trials?

Yes, including a randomized, controlled proof-of-concept trial for postoperative ileus after bowel resection surgery ^[16], and human pharmacokinetic-pharmacodynamic modeling work ^[13]. These are real controlled human studies, though they test specific medical use cases, not general performance or anti-aging claims.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin is characterized as the first selective growth hormone secretagogue, releasing GH with minimal cortisol, aldosterone, or prolactin rise
2. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptide applications, challenges, and future directions in orthopaedics
3. American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer on injectable peptide therapy for orthopaedic and sports medicine physicians
4. Sports Medicine (Auckland), 2026 (PMID 41966639): Assesses safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance
5. Translational Andrology and Urology, 2020 (PMID 32257855): Discusses growth hormone secretagogues for body composition management in hypogonadal males
6. International Journal of Molecular Sciences, 2026 (PMID 42123471): Reviews therapeutic peptides in aesthetic, metabolic, and endocrine conditions including safety data
7. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Ghrelin mimetics attenuate visceral and somatic nociception in preclinical models
8. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes the development of novel orally active growth hormone secretagogues, the compound class MK-677 belongs to
9. JBJS Reviews, 2026 (PMID 42160466): Narrative review of injectable peptides in sports medicine covering antidoping implications
10. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induces longitudinal bone growth in rats
11. Histology and Histopathology, 2002 (PMID 12168778): Chronic ipamorelin treatment affects somatotroph response in young female rats
12. Pharmaceutical Research, 1999 (PMID 10496658): Human pharmacokinetic-pharmacodynamic modeling of ipamorelin describes a short-acting release pattern
13. Growth Hormone & IGF Research, 2009 (PMID 19231263): GH and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats
14. Drug Testing and Analysis, 2015 (PMID 25869809): Describes methods for detecting growth hormone releasing peptide metabolites including ipamorelin in human urine after nasal administration
15. International Journal of Colorectal Disease, 2014 (PMID 25331030): Randomized controlled proof-of-concept study of ipamorelin for postoperative ileus in bowel resection patients
16. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of black market growth-promoting products found quality and identity problems in unregulated peptide products
17. Xenobiotica, 1998 (PMID 9879640): Pharmacokinetic evaluation of ipamorelin and related peptidyl secretagogues including nasal absorption route
18. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Ipamorelin efficacy on gastric dysmotility in a rodent model of postoperative ileus
19. Journal of Pharmacology and Experimental Therapeutics, 2009 (PMID 19289567): Ipamorelin efficacy in a rodent model of postoperative ileus
20. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats
21. Frontiers in Aging, 2026 (PMID 42021992): Reviews therapeutic peptides in gerontology, mechanisms and applications for healthy aging
22. Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increase bone mineral content in adult female rats
23. Neuro Endocrinology Letters, 2004 (PMID 15665799): Describes the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats
24. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): GH secretagogues can stimulate adiposity through a GH-independent mechanism in animal models
25. FDA, Drugs@FDA database: Confirms neither ipamorelin nor MK-677 is an FDA-approved drug product
26. eCFR, 21 CFR 216.24 (503B Bulks List): Establishes the bulk drug substances list applicable to 503B outsourcing facility compounding
27. Cornell Law, 21 U.S.C. 353a: Establishes the federal pharmacy compounding framework governing substances like compounded ipamorelin
28. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains FDA's process for determining which bulk substances may be used in 503A pharmacy compounding
29. eCFR, 21 CFR 216.23 (503A Bulks List): Lists bulk drug substances that may be used under section 503A compounding
30. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): Tracks the current status of bulk drug substance nominations including peptides under FDA review